Rhythm Pharmaceuticals Inc (RYTM) Stock Price, Quote & News

Company Profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 264 4280

Fax: 857 264 4299

Website: rhythmtx.com

Address:

222 Berkeley Street, 12th Floor, Boston, United States

Stonky_Mcprofitface Jun. 5 at 1:00 AM

$RYTM There is one ill-advised holdout. https://www.cnbc.com/2026/06/04/biotech-ma-dealmaking-pharma-106-billion.html?&qsearchterm=biotech

0 · Reply

SportTrade Jun. 4 at 8:08 PM

$PTN $RYTM $LLY If you are a serious investor in PTN then listen to RYTM’s public presentation today at Jefferies linked below: They talk about their hypothalamic obesity launch already strong with newly approved once daily injectable and their next gen approaches to weekly dosing or oral would be extremely valuable along with less hyperpigmentation a holy grail to prevent discontinuation. Also confidence in large addressable population that will grow over time as next gen treatments become avail. Further validation that Palatin’s move to differentiate with next gen compounds was a valuable move positioning them for success. Making them even more attractive to strategic BP interested in the high value markets of neuro endocrine diseases: HO, BBS, PWS, etc. PTN’s current ~$15M (million) enterprise value vs RYTM’s ~$6B EV offers incredible buying oppty IMO. Be patient thesis has not changed! https://ir.rhythmtx.com/events/event-details/jefferies-global-healthcare-conference/

1 · Reply

Stonky_Mcprofitface Jun. 1 at 4:30 PM

$RYTM Hyperinsulism target being announced soon. PWS could be huge for company.

0 · Reply

vjtweet May. 29 at 2:38 AM

$RYTM setting up for the move..

0 · Reply

AIBioScanner May. 25 at 6:30 AM

$RYTM AI-Based Findings on RYTM After running RYTM through my AI-driven quantitative framework, the stock is in a sideways/mixed trend with price trading near both moving averages with no clear directional pressure. RYTM is trading around $87.84, near both the 20-day (~$88.94) and 50-day (~$87.07) moving averages — indicating indecision and softening structure. Key signals: • Trading near both MAs — sideways/mixed trend • MACD positive (0.55) — bullish momentum • Range between ~$81.36 support and ~$96.61 resistance 1-Month Outlook: Base scenario: consolidation near $83.45–$92.23 Breakout above $92.23 could open a move toward $107.91 Breakdown below $83.45 may extend further downside toward $68.43 Structure is neutral-to-mixed. Requires strong volume confirmation for any reversal. Not financial advice.

0 · Reply

justiceforb_85 May. 25 at 1:34 AM

$RYTM how are folks feeling about upcoming data for setmelanotide in PWS?

1 · Reply

Stonky_Mcprofitface May. 22 at 6:22 PM

$RYTM Every Friday- huge selloff.

0 · Reply

SportTrade May. 22 at 4:09 PM

$PTN $RYTM $VKTX $LLY Flagging that Palatin’s ($PTN) uplisting to Nasdaq on May 29th is a major structural catalyst the market is completely ignoring. AT a microscopic $26M market cap, the stock is deeply disconnected from its underlying asset value, largely because alternative exchanges like the NYSE American are completely walled off from major institutional healthcare funds and passive index mandates. Moving to the Nasdaq removes these compliance barriers, creating an automated pipeline of non-discretionary buying that could easily drive a 40% to 75% mechanical upward re-rating as the new bid enters a highly illiquid order book. If this newfound institutional demand triggers a short squeeze among trapped bears alongside a retail momentum chase, the upside potential quickly stretches to 100%–180% as the free float gets entirely locked up. For patient investors tracking the next-gen obesity landscape, the current valuation is a screaming buy ahead of next Friday's opening bell IMO.

3 · Reply

WallStWireAds May. 20 at 12:33 PM

$PTN Ozempic Doesn't Work for Every Form of Obesity. Palatin Technologies Is Targeting the Patients It Misses. >> https://www.bioreview.com/ozempic-doesnt-work-for-every-form-of-obesity-palatin-technologies-is-targeting-the-patients-it-misses/ $RYTM

1 · Reply

Quantumup May. 20 at 11:34 AM

Piper Sandler⬆️ $DRUG's PT to $220, reit'd at Overweight/said—We caught up with DRUG following earnings, where mgmt reflected confidence in the progress made across programs this past quarter. SLNO - NBIX HRMY $RYTM LBPH - HLUBF / HLBBF PFE UCBJY STOK - BIIB JAZZ $PRAX XENE OVID Here's what else Piper Sandler had to say: https://x.com/Quantumup1/status/2057061836768329992?s=20

0 · Reply

Rhythm Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

May 29, 2026, 8:00 AM EDT - 6 days ago

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

May 29, 2026, 8:00 AM EDT - 6 days ago

Rhythm Pharmaceuticals Proxy statement: Proxy filing

May 28, 2026, 8:00 AM EDT - 7 days ago

Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics

May 26, 2026, 8:00 AM EDT - 9 days ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

May 26, 2026, 7:00 AM EDT - 9 days ago

Rhythm Pharmaceuticals Slides: Corporate presentation

May 13, 2026, 6:00 PM EDT - 22 days ago

Rhythm Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 8:00 AM EDT - 23 days ago

Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology

2026-05-07T16:30:44.000Z - 4 weeks ago